<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/AIMS: To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of <z:hpo ids='HP_0000713'>agitation</z:hpo> and <z:hpo ids='HP_0000718'>aggression</z:hpo> in patients with <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's disease</z:e>, vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> or both </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This is an 8-week, multicenter, randomized, double-blind, placebo-controlled trial carried out independently of the pharmaceutical industry </plain></SENT>
<SENT sid="2" pm="."><plain>Changes in the <z:hpo ids='HP_0000713'>agitation</z:hpo> and <z:hpo ids='HP_0000718'>aggression</z:hpo> subscore of the Neuropsychiatric Inventory (NPI) were the primary outcomes </plain></SENT>
<SENT sid="3" pm="."><plain>The secondary out- comes were the changes in the caregivers' total burden scores (measured by the NPI) and changes in the Brief <z:hpo ids='HP_0000713'>Agitation</z:hpo> Rating Scale (BARS) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: In total, 103 institutionalized patients at 35 sites were randomized to the trial </plain></SENT>
<SENT sid="5" pm="."><plain>After 8 weeks, no statistically significant differences were found between the 2 groups for <z:hpo ids='HP_0000001'>all</z:hpo> outcomes </plain></SENT>
<SENT sid="6" pm="."><plain>A trend was observed in favor of the OXC group in the reduction in the scores on the BARS (p = 0.07) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: This study found no significant effect of OXC in treatment of <z:hpo ids='HP_0000713'>agitation</z:hpo> and <z:hpo ids='HP_0000718'>aggression</z:hpo> in patients with <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
</text></document>